Lee DC, Schlienz NJ, Herrmann ES, Martin EL, Leoutsakos J, Budney AJ, Tompkins DA, Hampson AJ, & Vandrey R. Randomized controlled trial of zolpidem as a pharmacotherapy for cannabis use disorder. Journal of Substance Use and Addiction Treatment. (2023).
Martin EL, Baker NL, Sempio C, Christians U, Klawitter J, & McRae-Clark AL. Sex differences in endocannabinoid tone in a pilot study of cannabis use disorder and acute cannabis abstinence. Addiction Biology. (2023).
Martin EL, Neelon B, Brady KT, Guille C, Baker NL, Ramakrishnan V, Gray KM, Saladin ME, & McRae-Clark AL. Differential prevalence of Adverse Childhood Experiences (ACEs) by gender and substance used in individuals with cannabis, cocaine, opioid, and tobacco use disorders. The American Journal of Drug and Alcohol Abuse. (2023).
Garcia-Romeu A, Elmore J, Mayhugh RE, Schlienz NJ, Martin EL, Strickland JC, Bonn-Miller M, Jackson H, & Vandrey R. Online survey of medicinal cannabis users: qualitative analysis of patient-level data. Frontiers in Pharmacology. (2022).
Sholler DJ, Zamarripa CA, Spindle TR, Martin EL, Kuntz D, Vandrey R, & Grabenauer M. Urinary excretion profile of cannabinoid analytes following acute administration of oral and vaporized cannabis in infrequent cannabis users. Journal of Analytical Toxicology. (2022).
Martin EL, Strickland JC, Schlienz NJ, Munson J, Jackson H, Bonn-Miller MO, & Vandrey R. Antidepressant and anxiolytic effects of medicinal cannabis use in an observational trial. Frontiers in Psychiatry. (2021).
Strickland JC, Jackson H, Schlienz NJ, Salpekar J, Martin EL, Munson J, Bonn-Miller MO, & Vandrey R. Cross-sectional and longitudinal evaluation of cannabidiol (CBD) product use and health among people with epilepsy. Epilepsy & Behavior. (2021).
Martin EL, Doncheck EM, Reichel CM, & McRae-Clark AL. Consideration of sex as a biological variable in the translation of pharmacotherapy for stress-associated drug seeking. Neurobiology of Stress. (2021).
Spindle TR, Martin EL, Grabenauer M, Woodward T, Milburn M, & Vandrey R. Assessment of cognitive and psychomotor impairment, subjective effects, and blood THC concentrations following acute administration of oral and vaporized cannabis. Journal of Psychopharmacology. (2020).
Martin EL & McRae-Clark AL. Evidence for the endocannabinoid system as a therapeutic target in the treatment of cannabis use disorder. Current Addiction Reports. (2020).
Schlienz NJ, Scalsky R, Martin EL, Jackson H, Munson J, Strickland JC, Bonn-Miller MO, Loflin M, & Vandrey R. A cross-sectional and prospective comparison of medicinal cannabis users and controls on self-reported health. Cannabis and Cannabinoid Research. (2020).